Painceptor Pharma gains patent for lead drug
The four patents granted PainCeptor are:
1. 'Neurotrophin Antagonists for the Treatment of Epilepsy, Alzheimer's Disease and Pain'' - patent allowed in Europe (#0930883) and Israel (#129475)
2. 'Method of Inhibiting Neurotrophin-Receptor Binding'' - patent issued in Australia (#781888)
3. "DNA Encoding a Human Proton-Gated Ion Channel and Uses Thereof'' - patent allowed in Europe (#EP-B-1025226)
4. "Method of Inhibiting Neurotrophin-Receptor Binding'' - US Divisional Patent allowed
These patents bring the total of PainCeptor's intellectual property portfolio to 39 issued patents; with an additional 45 patent applications under examination; and a further 10 provisional applications pending.
Most read news
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.